Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating activities:
Net loss	$ (21,348)	$ (11,556)
Items not involving cash:
Depreciation	179	302
Amortization of discount on term loan	255	164
Deferred income tax recovery	(11)	(61)
Stock-based compensation	955	1,363
Unrealized foreign exchange (gain) loss	(225)	406
Gain on termination of collaboration agreement (note 9c)		(4,398)
Changes in operating assets and liabilities:
Accounts receivable	(15)	324
Prepaid expenses, and other current assets	522	(193)
Prepaid expenses, long term		230
Accounts payable and accrued expenses	2,388	(338)
Net cash used in operating activities	(17,300)	(13,757)
Investing activities:
Purchases of property, plant and equipment	(600)	(318)
Purchases of marketable securities	(64,176)	(17,911)
Proceeds from marketable securities	51,002	25,146
Net cash provided by (used in) investing activities	(13,774)	6,917
Financing activities:
Proceeds from issuance of second tranche under term loan, net of issuance costs		4,989
Issuance of common shares, net of issuance costs (note 9a)		28,957
Issuance of common shares pursuant to exercise of stock options	69	182
Net cash provided by financing activities	69	34,128
Effect of exchange rate changes on cash and cash equivalents	326	(339)
Increase (decrease) in cash and cash equivalents	(30,679)	26,949
Cash and cash equivalents, beginning of period	67,754	20,486
Cash and cash equivalents, end of period	37,075	47,435
Supplemental disclosures:
Interest paid	468	164
Interest received	1,269	289
Cash paid for operating lease	314	304
Supplemental disclosures of non-cash transactions:
Fair value of stock options exercised on a cashless basis	$ 9	212
Issuance of preferred shares in exchange for common shares (note 9b)		21,825
Teva Pharmaceuticals International GmbH and Teva Canada Limited [Member]
Supplemental disclosures of non-cash transactions:
Termination of Teva agreement through cancellation of common shares (note 9c)		$ 4,470